Manmeet Singh Soni - 05 May 2023 Form 4 Insider Report for REATA PHARMACEUTICALS INC

Role: COO, CFO and President
Signature: /s/ Tracy Herson, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 05 May 2023
Net transactions value: $0
Form type: 4
Filing time: 09 May 2023, 16:35:58 UTC
Previous filing: 08 Mar 2023
Next filing: 17 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RETA	Class A common stock	Award	$0	+50,000	+57%	$0.000000	138,304	05 May 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RETA	Employee Stock Option (right-to-buy)	Award	$0	+50,000		$0.000000	50,000	05 May 2023	Class B common stock	50,000	$104.79	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On August 29, 2019, the reporting person was granted 50,000 Restricted Stock Units subject to performance criteria. On May 5, 2023, based on the satisfaction of certain performance criteria, the 50,000 RSUs vested.
F2	On August 29, 2019, the reporting person was granted an option to purchase 50,000 shares of Class B common stock subject to performance criteria. On May 5, 2023, based on the satisfaction of certain performance criteria, the option vested as to 50,000 shares.